Endothelin-1 stimulates small artery VCAM-1 expression through p38MAPK-dependent neutral sphingomyelinase

Journal of Vascular Research

Volumn 49, Issue 4, 2012, Pages 353-362

  Ohanian, Jacqueline ^a   Forman, Simon P ^a   Katzenberg, Gideon ^a   Ohanian, Vasken ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Endothelial cells; Inflammation; Signal transduction; Smooth muscle; Vascular remodelling

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ENDOTHELIN 1; GW 4869; MITOGEN ACTIVATED PROTEIN KINASE P38; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANILINE COMPOUNDS; ANIMALS; BENZYLIDENE COMPOUNDS; ENDOTHELIN-1; HSP27 HEAT-SHOCK PROTEINS; IMIDAZOLES; MESENTERIC ARTERIES; OLIGOPEPTIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES, CYCLIC; PIPERIDINES; PYRIDINES; RATS; RECEPTOR, ENDOTHELIN B; SPHINGOMYELIN PHOSPHODIESTERASE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84861336893     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000336649     Document Type: Article

References (57)

1. Intengan HD, Schiffrin EL: Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587.
2. Brunner F, Brás-Silva C, Cerdeira AS, Leite-Moreira AF: Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacology Ther 2006; 111: 508-531. (Pubitemid 43832003)
3. Schiffrin EL: State-of-the-art lecture: role of endothelin-1 in hypertension. Hypertension 1999; 34: 876-881. (Pubitemid 29501316)
4. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL: Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004; 110: 2233-2240. (Pubitemid 39372507)
5. Amiri F, Paradis P, Reudelhuber TL, Schiffrin EL: Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. J Hypertens 2008; 26: 1102-1109. (Pubitemid 351670501)
6. Böhm F, Pernow J: The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007; 76: 8-18. (Pubitemid 47362047)
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415. (Pubitemid 18090241)
8. Murohara T, Lefer AM: Autocrine effects of endothelin-1 on leukocyte-endothelial interaction: stimulation of endothelin B receptor subtype reduces endothelial adhesiveness via a nitric oxide-dependent mechanism. Blood 1996; 88: 3894-3900. (Pubitemid 26383113)
9. Ishizuka T, Takamizawa-Matsumoto M, Suzuki K, Kurita A: Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells. Eur J Pharmacol 1999; 369: 237-245. (Pubitemid 29129564)
10. Waters CE, Shi-Wen X, Denton CP, Abraham DJ, Pearson JD: Signaling pathways regulating intercellular adhesion molecule 1 expression by endothelin 1: comparison with interleukin-1 in normal and scleroderma dermal fibroblasts. Arthritis Rheum 2006; 54: 649-660. (Pubitemid 43228644)
11. Hayasaki Y, Nakajima M, Kitano Y, Iwasaki T, Shimamura T, Iwaki K: ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype. Biochem Biophys Res Commun 1996; 229: 817-824. (Pubitemid 27035801)
12. Anggrahini DW, Emoto N, Nakayama K, Widyantoro B, Adiarto S, Iwasa N, Nonaka H, Rikitake Y, Kisanuki YY, Yanagisawa M, Hirata K: Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. Cardiovasc Res 2009; 82: 143-151.
13. Li L, Chu Y, Fink GD, Engelhardt JF, Heistad DD, Chen AF: Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension 2003; 42: 997-1003. (Pubitemid 37413744)
14. Ferri C, Bellini C, Desideri G, Giuliani E, De Siati L, Cicogna S, Santucci A: Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Hypertension 1998; 32: 862-868. (Pubitemid 28530220)
15. Cottone S, Mulè G, Amato F, Riccobene R, Vadalà A, Lorito MC, Raspanti F, Cerasola G: Amplified biochemical activation of endothelial function in hypertension associated with moderate to severe renal failure. J Nephrol 2002; 15: 643-648. (Pubitemid 36040564)
16. Schorlemmer A, Matter ML, Shohet RV: Cardioprotective signaling by endothelin. Trends Cardiovasc Med 2008; 18: 233-239.
17. Cuenda A, Rousseau S: p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773: 1358-1375. (Pubitemid 47125981)
18. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22: 153-183. (Pubitemid 32458157)
19. Touyz RM, He G, El Mabrouk M, Diep Q, Mardigyan V, Schiffrin EL: Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activatedprotein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. J Hypertens 2001; 19: 553-559. (Pubitemid 32280947)
20. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM: Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 2011; 13:e11.
21. Cuadrado A, Nebreda AR: Mechanisms and functions of p38 MAPK signalling. Biochem J 2010; 429: 403-417.
22. Hoefer J, Azam MA, Kroetsch JTE, Poi HL, Momen MA, Voigtlaender-Bolz J, Scherer EQ, Meissner A, Bolz S-S, Husain M: Sphingosine-1-phosphate-dependent activation of p38 MAPK maintains elevated peripheral resistance in heart failure through increased myogenic vasoconstriction. Circ Res 2010; 107: 923-933.
23. Yogi A, Callera GE, Aranha AB, Antunes TT, Graham D, Mcbride M, Dominiczak A, Touyz RM: Sphingosine-1-phosphate-induced inflammation involves receptor tyrosine kinase transactivation in vascular cells: upregulation in hypertension. Hypertension 2011; 57: 809-818.
24. Wang C, Liu J, Guo F, Ji Y, Liu N: Endothelin-1 induces the expression of C-reactive protein in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2009; 389: 537-542.
25. Kubo T, Ibusuki T, Chiba S, Kambe T, Fukumori R: Mitogen-activated protein kinase activity regulation role of angiotensin and endothelin systems in vascular smooth muscle cells. Eur J Pharmacol 2001; 411: 27-34. (Pubitemid 32013108)
26. Clarke C, Truong T, Hannun Y: Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem 2007; 282: 1384-1396. (Pubitemid 47076577)
27. Filosto S, Fry W, Knowlton AA, Goldkorn T: Neutral sphingomyelinase 2 (nSMase2) is a phosphoprotein regulated by calcineurin (PP2B). J Biol Chem 2010; 285: 10213-10222.
28. Ohanian J, Ohanian V: Sphingolipids in mammalian cell signalling. Cell Mol Life Sci 2001; 58: 2053-2068. (Pubitemid 34016975)
29. Alewijnse AE, Peters SLM: Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol 2008; 585: 292-302.
30. Pavoine C, Pecker F: Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 2009; 82: 175-183.
31. Clarke C, Snook C, Tani M, Matmati N, Marchesini N, Hannun Y: The extended family of neutral sphingomyelinases. Biochemistry 2006; 45: 11247-11256. (Pubitemid 44453973)
32. Cogolludo A, Moreno L, Frazziano G, Moral-Sanz J, Menendez C, Castaneda J, Gonzalez C, Villamor E, Perez-Vizcaino F: Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction. Cardiovasc Res 2008; 82: 296-302.
33. Barsacchi R, Perrotta C, Bulotta S, Moncada S, Borgese N, Clementi E: Activation of endothelial nitric-oxide synthase by tumor necrosis factor-alpha: a novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3, kinase, and Akt. Mol Pharmacol 2003; 63: 886-895. (Pubitemid 36368996)
34. De Palma C, Meacci E, Perrotta C, Bruni P, Clementi E: Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vasc Biol 2006; 26: 99-105. (Pubitemid 43732234)
35. Catalán RE, Aragonés MD, Martínez AM, Fernández I: Involvement of sphingolipids in the endothelin-1 signal transduction mechanism in rat brain. Neurosci Lett 1996; 220: 121-124. (Pubitemid 26426599)
36. Ohanian J, Cunliffe P, Ceppi E, Alder A, Heerkens E, Ohanian V: Activation of p38 mitogen-activated protein kinases by endothelin and noradrenaline in small arteries, regulation by calcium influx and tyrosine kinases, and their role in contraction. Arterioscler Thromb Vasc Biol 2001; 21: 1921-1927. (Pubitemid 34219742)
37. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, Smith GK: Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 2002; 277: 41128-41139. (Pubitemid 35215704)
38. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M, Yano M: Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992; 50: 247-255.
39. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T: Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 1994; 91: 4892-4896. (Pubitemid 24177756)
40. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
41. Loidl A, Claus R, Deigner HP, Hermetter A: High-precision fluorescence assay for sphingomyelinase activity of isolated enzymes and cell lysates. J Lipid Res 2002; 43: 815-823. (Pubitemid 34477909)
42. Madonna R, Montebello E, Lazzerini G, Zurro M, De Caterina R: NA +H+ exchanger 1-and aquaporin-1-dependent hyperosmolarity changes decrease nitric oxide production and induce VCAM-1 expression in endothelial cells exposed to high glucose. Int J Immunopathol Pharmacol 2010; 23: 755-765.
43. Niu XF, Smith CW, Kubes P: Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res 1994; 74: 1133-1140. (Pubitemid 24176908)
44. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ: Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008; 52: 452-459.
45. Rutkute K, Karakashian AA, Giltiay NV, Dobierzewska A, Nikolova-Karakashian MN: Aging in rat causes hepatic hyperresponsiveness to interleukin-1, which is mediated by neutral sphingomyelinase-2. Hepatology 2007; 46: 1166-1176. (Pubitemid 350144781)
46. Schiffrin EL: Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001; 14: 83S-89S. (Pubitemid 32506701)
47. Wang H, Chen AF, Watts SW, Galligan JJ, Fink GD: Endothelin in the splanchnic vascular bed of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 288:H729-H736. (Pubitemid 40139657)
48. Larivière R, Day R, Schiffrin EL: Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1993; 21: 916-920. (Pubitemid 23166939)
49. Schiffrin EL, Larivière R, Li JS, Sventek P: Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res 1996; 33: 235-248. (Pubitemid 26164473)
50. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF: Endothelin-1 increases vascular superoxide via endothelin(a)-nadph oxidase pathway in low-renin hypertension. Circulation 2003; 107: 1053-1058. (Pubitemid 36258731)
51. Clarke CJ, Wu BX, Hannun YA: The neutral sphingomyelinase family: identifying biochemical connections. Adv Enzyme Regul 2011; 51: 51-58.
52. Levy M, Castillo SS, Goldkorn T: NSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. Biochem Biophys Res Commun 2006; 344: 900-905.
53. Levy M, Khan E, Careaga M, Goldkorn T: Neutral sphingomyelinase 2 is activated by cigarette smoke to augment ceramide-induced apoptosis in lung cell death. Am J Physiol Lung Cell Mol Physiol 2009; 297:L125-L133.
54. Iwasa S, Fan J, Shimokama T, Nagata M, Watanabe T: Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions: a possible role in atherogenesis. Atherosclerosis 1999; 146: 93-100. (Pubitemid 29371866)
55. Thorin E, Webb DJ: Endothelium-derived endothelin-1. Pflügers Arch 2010; 459: 951-958.
56. Hannun YA, Obeid LM: Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139-150. (Pubitemid 351158911)
57. Kim T-J, Kang Y-J, Lim Y, Lee H-W, Bae K, Lee Y-S, Yoo J-M, Yoo H-S, Yun Y-P: Ceramide 1-phosphate induces neointimal formation via cell proliferation and cell cycle progression upstream of ERK1/2 in vascular smooth muscle cells. Exp Cell Res 2011; 317: 2041-2051.